Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Identification of native, immunogenic peptides from Cyclin D1

Leukemia volume 24, pages 209–211 (2010)Cite this article

In their study Wang et al.1 clearly characterize Cyclin D1 as a tumor antigen in mantle cell lymphoma. They show that T cells specific for the epitope LLGATCMFV (p101) can be generated from peripheral blood of normal donors and cancer patients that recognized HLA-matched primary tumor cells. Surprisingly, the authors report that they had to choose a heteroclitic approach due to a lack of a high-affinity natural epitope within the protein.

The authors chose not to characterize p22 as an immunogen due to low solubility of the heteroclitic peptide. On the basis of the results from our HLA-binding studies we did indeed attempt expansion of Cyc22 (p22) specific CD8+ T cell, which was successful in 2/2 donors.3 Furthermore, using the above strategy we identified p228 (RLTRFLSRV) as an immunogenic HLA-A0201-binding peptide that is recognized by T cells. (Figure 1a, b)

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 2009; 23: 1320–1328.

    Article  CAS  Google Scholar 

  2. Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res 2008; 14: 6574–6579.

    Article  CAS  Google Scholar 

  3. Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS . Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J Immunother 2009; 32: 157–160.

    Article  CAS  Google Scholar 

  4. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ . Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998; 28: 193–200.

    Article  CAS  Google Scholar 

  5. Kessler JH, Melief CJ . Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007; 21: 1859–1874.

    Article  CAS  Google Scholar 

  6. Alexander-Miller MA, Leggatt GR, Berzofsky JA . Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93: 4102–4107.

    Article  CAS  Google Scholar 

  7. Kondo E, Maecker B, Draube A, Klein-Gonzalez N, Shimabukuro-Vornhagen A, Schultze JL et al. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells. Int J Cancer 2009, E-pub ahead of print 8 June 2009, DOI: 10.1002/ijc.24629.

    Article  CAS  Google Scholar 

  8. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N et al. Unmodified self antigen triggers human CD8T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008; 105: 3849–3854.

    Article  CAS  Google Scholar 

  9. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 1377–1382.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department I of Internal Medicine, Laboratory for Tumor and Transplantation Immunology, University Hospital of Cologne, Cologne, Germany

    M S von Bergwelt-Baildon & A Shimabukuro-Vornhagen

  2. Department I of Internal Medicine, Stem Cell Transplantation Program, University Hospital of Cologne, Cologne, Germany

    M S von Bergwelt-Baildon & A Shimabukuro-Vornhagen

  3. Department I of Internal Medicine, Laboratory for Molecular Biology and Immunology of CLL, University Hospital of Cologne, Cologne, Germany

    C M Wendtner

  4. Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan

    E Kondo

Authors
  1. M S von Bergwelt-Baildon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Shimabukuro-Vornhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C M Wendtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M S von Bergwelt-Baildon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Bergwelt-Baildon, M., Shimabukuro-Vornhagen, A., Wendtner, C. et al. Identification of native, immunogenic peptides from Cyclin D1. Leukemia 24, 209–211 (2010). https://doi.org/10.1038/leu.2009.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.184

Search

Advanced search

Quick links